Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N S Kleiman

Showing results (1-10 of 135) with videos related to

Pageof 14
Sort By:
American Heart Journal|September 29, 1999
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitorsN S Kleiman
The American Journal of Cardiology|August 18, 1997
Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisN S Kleiman
Drugs in R&D|November 24, 1999
GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiologyN S Kleiman
The American Journal of Cardiology|November 4, 1991
Goals of thrombolytic therapyN S Kleiman
Coronary Artery Disease|July 1, 1996
Clinical trials of conjunctive anticoagulant strategies in thrombolysisN S Kleiman
European Heart Journal|November 1, 1995
Description of patients undergoing high risk angioplasty. Analyses of various databasesN S Kleiman
Drug Safety|February 6, 1999
A risk-benefit assessment of abciximab in angioplastyN S Kleiman
Coronary Artery Disease|December 23, 1998
Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonistsN S Kleiman
American Heart Journal|January 30, 1999
Much ado about thrombinN S Kleiman
Circulation|February 1, 1994
Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a 'new diagnostic mind-set'R Roberts, N S Kleiman
Pageof 14

Showing results (1-10 of 135) with videos related to

Sort By:
Pageof 14
American Heart Journal|September 29, 1999
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitorsN S Kleiman
The American Journal of Cardiology|August 18, 1997
Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisN S Kleiman
Drugs in R&D|November 24, 1999
GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiologyN S Kleiman
The American Journal of Cardiology|November 4, 1991
Goals of thrombolytic therapyN S Kleiman
Coronary Artery Disease|July 1, 1996
Clinical trials of conjunctive anticoagulant strategies in thrombolysisN S Kleiman
European Heart Journal|November 1, 1995
Description of patients undergoing high risk angioplasty. Analyses of various databasesN S Kleiman
Drug Safety|February 6, 1999
A risk-benefit assessment of abciximab in angioplastyN S Kleiman
Coronary Artery Disease|December 23, 1998
Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonistsN S Kleiman
American Heart Journal|January 30, 1999
Much ado about thrombinN S Kleiman
Circulation|February 1, 1994
Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a 'new diagnostic mind-set'R Roberts, N S Kleiman
Pageof 14